Veklury is indicated for the treatment of COVID-19 in adults and adolescents (aged 12 years and older and weighing at least 40 kg) with pneumonia requiring supplemental oxygen.Given the alarming levels of the spread of the pandemic and the urgent need for a treatment, the conditional marketing authorization was granted based on a rolling review of supporting data that began in April 2020.